Physician-diagnosed COPD GOLD stage IV in Östersund, Sweden: prevalence and patient characteristics Source: Eur Respir J 2006; 28: Suppl. 50, 447s Year: 2006
COPD GOLD stage 1: Is it really a disease? Source: Annual Congress 2011 - COPD mechanisms Year: 2011
Validation of non-spirometric predictors of COPD to the GOLD stage classification Source: Eur Respir J 2002; 20: Suppl. 38, 123s Year: 2002
Stage 0 in GOLD does not predict future clinical COPD Source: Eur Respir J 2002; 20: Suppl. 38, 401s Year: 2002
Is GOLD stage 0 a good predictor of the development of COPD? Preliminary results from the ECRHS II Source: Eur Respir J 2005; 26: Suppl. 49, 434s Year: 2005
Comorbidities in stage IV COPD patients Source: Annual Congress 2011 - COPD management Year: 2011
Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017
Use of quality of life measures and FEF25-75 to stratify GOLD stage I COPD into stage IA and stage IB Source: Eur Respir J 2002; 20: Suppl. 38, 122s Year: 2002
Discovery of novel disease-related biomarkers for GOLD stage II COPD: A prospective exploratory clinical study Source: Annual Congress 2010 - Novel mechanisms in COPD Year: 2010
The prevalence of QTc-prolongation increase by GOLD stage in COPD Source: International Congress 2017 – Prevalence, prognosis and comorbidities of COPD and factors associated with lung function Year: 2017
GOLD stage 0 and risk of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 352s Year: 2003
Rehabilitation programs in patients in different severity stage of COPD (GOLD II-to-IV): analysis of the results Source: Eur Respir J 2005; 26: Suppl. 49, 69s Year: 2005
Relation of various parameters to the survival rate in stage 0 to stage IIa chronic obstructive pulmonary disease (COPD) according to the GOLD guidelines Source: Eur Respir J 2003; 22: Suppl. 45, 578s Year: 2003
Impact of comorbidities on survival of patients with COPD according to GOLD stages Source: Annual Congress 2011 - COPD: burden of disease, imaging and management Year: 2011
The frequent exacerbator phenotype in bronchiectasis: predictors and particularities Source: International Congress 2018 – The importance of the pulmonary function test in different clinical settings Year: 2018
Prediction of the clinical course of COPD using the old and the new GOLD classification Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD Year: 2012
Impact of symptomatology in patients with GOLD stage I COPD Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010
Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification Source: Eur Respir J 2013; 42: 647-654 Year: 2013
Late Breaking Abstract - Adherence to GOLD recommendations in Italian patients with COPD categorised as frequent and non-frequent exacerbators: The MISTRAL study Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017
Effect of COPD severity on hemodynamic responses to exercise in patients with GOLD stages I-IV Source: Annual Congress 2011 - Exercise tests and emerging outcomes: defining the impact of pulmonary rehabilitation Year: 2011